Consistently, several previous retrospective studies demonstrated that BMs did not significantly correlate with survival outcomes in advanced NSCLC patients treated with nivolumab, an anti-PD1 agent (45–47). Here, PDCD1 is linked to non-small cell lung carcinoma.